Preferentially activates amylin receptors. Laboratory studies also found weaker calcitonin receptor activity; the targets do not have equal potency, and their separate contributions to weight loss are not established.
Adults with obesity or overweight and type 2 diabetes
Efficacy estimand assumes continued intervention through 48 weeks, allowing dose interruptions/modifications. Values rounded to one decimal in the sponsor release.
Safety context
GI adverse events predominated. Adverse-event discontinuation ranged from 0% to 10.8% across eloralintide monotherapy arms; the retrieved release does not assign that range to the 6 mg arm.
Limitations: This is a monotherapy arm of a 367-person multi-arm study, not 367 people receiving 6 mg. The 6 mg arm had the largest reported monotherapy HbA1c decrease; the 9 mg arm decreased by 1.3 pp. No durable diabetes-complication outcome or U.S. approval established.
Preferentially activates amylin receptors. Laboratory studies also found weaker calcitonin receptor activity; the targets do not have equal potency, and their separate contributions to weight loss are not established.
Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.
The molecule
Preferentially activates amylin receptors. Laboratory studies also found weaker calcitonin receptor activity; the targets do not have equal potency, and their separate contributions to weight loss are not established.
Structure not yet verified
Structure not verified
Preferentially activates amylin receptors. Laboratory studies also found weaker calcitonin receptor activity; the targets do not have equal potency, and their separate contributions to weight loss are not established.
Shown: Peptide drug
PubChem CID 175663130 does not encode stereochemistry (nonstereochemical InChIKey); its drawing was withheld as an exact-drug structure.
ClinicalTrials.gov records this as the actual study-start date for the phase 3 obesity trial without type 2 diabetes. It is not a results or approval milestone.
Diabetes monotherapy and EloraTZP combination readout
The NCT06603571 monotherapy 6 mg arm decreased HbA1c 1.4 pp versus 0.3 pp with placebo and weight 12.3% versus 3.0% at 48 weeks (rounded efficacy estimates). Separate eloralintide plus tirzepatide arms supported a planned co-formulated phase 3 program; these are distinct from the earlier non-diabetic monotherapy study.